Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0076-6879(97)79044-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mapping TcdB interactions with host cell-surface and intracellular factors using proximity-dependent biotinylation labeling.
mBio
January 2025
Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada.
Many bacterial toxins exert their cytotoxic effects by enzymatically inactivating one or more cytosolic targets in host cells. To reach their intracellular targets, these toxins possess functional domains or subdomains that interact with and exploit various host factors and biological processes. Despite great progress in identifying many of the key host factors involved in the uptake of toxins, significant knowledge gaps remain as to how partially characterized and newly discovered microbial toxins exploit host factors or processes to intoxicate target cells.
View Article and Find Full Text PDFA Water-Soluble Small Molecule Boron Carrier Targeting Biotin Receptors for Neutron Capture Therapy.
ACS Omega
December 2024
School of Life Science and Technology, Institute of Science Tokyo, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan.
A critical challenge in boron neutron capture therapy (BNCT) is expanding its effectiveness through the development of novel boron agents with different mechanisms of action than the approved drug 4-borono-l-phenylalanine (BPA). In this study, we developed a small molecule boron carrier, biotinyl--dodecaborate conjugate with an iodophenyl moiety (BBC-IP), incorporating biotin as a ligand for biotin receptors overexpressed in various cancer cells, alongside an albumin ligand and boron source. BBC-IP exhibited high water solubility, minimal cytotoxicity, and superior cellular uptake compared to BPA in both human and mouse cancer cells.
View Article and Find Full Text PDFA "plug-and-display" nanoparticle based on attenuated outer membrane vesicles enhances the immunogenicity of protein antigens.
J Control Release
December 2024
The State Key Laboratory of Pharmaceutical Biotechnology and Department of Neurology of Nanjing Drum Tower Hospital, School of Life Sciences and The Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing 210023, China; Changzhou High-Tech Research Institute of Nanjing University and Jiangsu TargetPharma Laboratories Inc, Changzhou 213164, China.
Article Synopsis
- Bacterial outer membrane vesicles (OMV) show promise as protein vaccine carriers due to their self-adjuvant properties and biocompatibility, but their use is limited by immunotoxicity.
- Researchers developed an enhanced version, EMV, by gene-editing to remove harmful proteins, resulting in reduced inflammatory responses in mouse models.
- EMV efficiently displays protein antigens and enhances dendritic cell uptake, leading to strong immune responses, making them a suitable candidate for vaccine delivery against various infectious diseases.
Pathway and protein channel engineering of for improved production of desthiobiotin and biotin.
Synth Syst Biotechnol
November 2024
Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China.
Biotin (vitamin B) is a crucial cofactor for various metabolic processes and has significant applications in pharmaceuticals, cosmetics, and animal feed. , a well-studied Gram-positive bacterium, presents a promising host for biotin production due to its Generally Recognized as Safe (GRAS) status, robust genetic tractability, and capacity for metabolite secretion. This study focuses on the metabolic engineering of .
View Article and Find Full Text PDFRecent advances in biotin-based therapeutic agents for cancer therapy.
Nanoscale
December 2024
Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266071, China.
Biotin receptors, as biomarkers for cancer cells, are overexpressed in various tumor types. Compared to other vitamin receptors, such as folate receptors and vitamin B12 receptors, biotin receptor-based targeting strategies exhibit superior specificity and broader potential in treating aggressive cancers, including ovarian cancer, leukemia, colon cancer, breast cancer, kidney cancer, and lung cancer. These strategies promote biotin transport receptor-mediated endocytosis, which is triggered upon ligand binding.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!